Page 2 - Tyme Technologies News Today

Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) major shareholder Michael Demurjian sold 53,097 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $0.25, for a total value of $13,274.25. Following the completion of the sale, the insider now owns 23,355,749 shares of the […]

25.05.2022 - - $84.0 million in cash and marketable securities as of March 31, 2022 -BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) - TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer ...

Tyme-10k_20220331.htm Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | May 25, 2022

Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) major shareholder Michael Demurjian sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The shares were sold at an average price of $0.32, for a total value of $12,800.00. Following the completion of the transaction, the insider now directly owns 23,648,846 […]

Mr. Dickey brings over 25 years of experience as a CFO and COO in private, public, and revenue stage companies with deep capital markets and business development transactional expertise across life science

Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) insider Steve Hoffman sold 78,125 shares of the firm’s stock in a transaction that occurred on Monday, March 28th. The stock was sold at an average price of $0.34, for a total value of $26,562.50. The transaction was disclosed in a document filed with the SEC, which can […]

BEDMINSTER, N.J., March 29, 2022 -- TYME Technologies, Inc. , an emerging biotechnology company developing cancer metabolism-based therapies , today announced that its Board of Directors has... | March 29, 2022

Kercheville Advisors LLC trimmed its holdings in shares of Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) by 61.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 271,020 shares of the company’s stock after selling 423,450 shares during the quarter. Kercheville […]

-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive...

EGRX earnings call for the period ending December 31, 2021.